BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2021

Boston Scientific Corporation (BSX) reported a significant increase in net sales for the year ended December 31, 2021, reaching $11.888 billion, a 19.9% increase compared to 2020. This growth was primarily driven by the recovery of elective and semi-emergent medical procedures, which were impacted by the COVID-19 pandemic in the prior year. The company's strategic acquisitions, including Preventice Solutions, Farapulse, and Lumenis's global surgical business, also contributed positively to the sales performance. While the company reported a net income of $985 million ($0.69 per diluted share), adjusted net income, excluding certain charges and credits, was $2.336 billion ($1.63 per diluted share), reflecting strong operational performance. The company's gross profit margin improved to 68.8% in 2021, up from 65.0% in 2020, attributed to higher sales volumes and a favorable product mix, though offset by inflationary pressures on raw materials and freight. Looking ahead, Boston Scientific is focused on its strategic imperatives, including strengthening category leadership and expanding into high-growth adjacencies. The company maintains a strong liquidity position with $1.925 billion in unrestricted cash and cash equivalents. However, ongoing challenges include managing supply chain disruptions, potential increases in costs, and navigating a dynamic regulatory and reimbursement landscape. The company also reported substantial litigation-related charges, particularly concerning transvaginal surgical mesh products. Despite these challenges, BSX demonstrated resilience and a clear growth trajectory in 2021, driven by its diverse product portfolio and strategic initiatives.